Willow vs Ro | Best GLP-1 Program 2026
Willow vs Ro: Willow offers compounded semaglutide and tirzepatide injections with guaranteed 3-day delivery at $249/month. Ro offers the FDA-approved oral semaglutide pill starting at $39. Two very different approaches, find out which is right for you.
Quick Verdict
Editorial Take
Best Overall: Willow - injection-based GLP-1 with both semaglutide and tirzepatide, plus a guaranteed 3-day delivery commitment
Best for Budget: Ro - lowest entry cost at $39 to get started, though ongoing medication costs vary
Best for Fast Approval: Willow - 3 days or less from approval to doorstep, vs standard pharmacy timelines with Ro
At a Glance Comparison
| Feature | Willow | Ro |
|---|---|---|
| Entry Cost | $249/month | $39 to get started |
| Medication Form | Compounded injections | FDA-approved oral pill (Wegovy pill) |
| Medications Available | Semaglutide & Tirzepatide | Oral semaglutide (Wegovy pill); no tirzepatide pill |
| Delivery Speed | 3 days or less (guaranteed) | Standard pharmacy delivery |
| Medication Type | Compounded (not FDA-approved brand) | FDA-approved brand name |
Who Should Choose Willow
Choose Willow if:
- ✓You want both semaglutide and tirzepatide with physician guidance on which is best for you
- ✓You are comfortable with weekly injections and want the highest-efficacy GLP-1 delivery method
- ✓You need medication quickly, Willow's 3-day guarantee removes the wait after approval
- ✓You want predictable all-inclusive pricing without variable pharmacy costs
- ✓You want the option to escalate to tirzepatide if semaglutide is insufficient
Who Should Choose Ro
Choose Ro if:
- ✓You want a daily oral pill rather than weekly injections, needle aversion is a real barrier
- ✓You prefer FDA-approved brand-name medication over a compounded formulation
- ✓The $39 entry cost lets you evaluate GLP-1 treatment with minimal financial risk
- ✓You value working with a large, established telehealth brand
- ✓A daily pill fits your routine better than a weekly injection schedule
Willow Deep Dive
Willow and Ro represent fundamentally different GLP-1 philosophies. Ro is built around a daily oral pill, FDA-approved, needle-free, low entry cost. Willow is built around weekly subcutaneous injections of semaglutide or tirzepatide with a 3-day shipping guarantee. Injection-based GLP-1 therapy has decades of clinical data and higher bioavailability than oral formats. Willow also offers tirzepatide, which has no oral equivalent from Ro. For patients willing to do weekly injections, Willow offers more clinical flexibility and faster delivery at a higher upfront cost.
How It Works
- Submit a detailed medical intake covering health history, current medications, and weight loss goals
- Licensed physician reviews intake, typically within 24 hours
- Prescription sent to an accredited compounding pharmacy
- Medication arrives in 3 days or less, guaranteed
- Monthly monitoring, dose adjustments, and refills managed by your physician
Medications Offered
- ✓Compounded Semaglutide injections, weekly subcutaneous injection, GLP-1 receptor agonist
- ✓Compounded Tirzepatide injections, weekly subcutaneous injection, dual GIP/GLP-1 receptor agonist
- ✓Physician-guided selection based on your goals and health history
Pricing
Willow charges $249/month all-inclusive, physician oversight, medication, and guaranteed 3-day delivery. Ro's $39 entry covers enrollment only; ongoing monthly medication costs vary by prescription and are not transparently presented upfront.
- ✓Both semaglutide and tirzepatide available, tirzepatide shows up to 22.5% body weight reduction vs semaglutide's 12-15%
- ✓Guaranteed 3-day delivery, faster than standard pharmacy timelines
- ✓Flat-rate transparent pricing, no variable pharmacy costs
- ✓No membership fees separate from the monthly program cost
- ✓Can switch from semaglutide to tirzepatide without changing providers
- ✗Higher entry cost, $249/month vs Ro's $39 to start
- ✗Injection-only, no oral option for needle-averse patients
- ✗Compounded medication is not FDA-approved as a finished drug product
- ✗Smaller brand footprint than Ro's established telehealth platform
Ro Deep Dive
Ro offers access to the FDA-approved Wegovy pill (oral semaglutide) at a $39 entry price. For needle-averse patients, a daily pill removes a real barrier to starting GLP-1 treatment. Ro carries credibility as one of the most recognized direct-to-consumer telehealth brands. The limitations: no tirzepatide (no oral version exists), and ongoing monthly medication costs after the $39 enrollment are variable and not as transparently published as Willow's flat rate.
How It Works
- Start online for $39, covers initial medical assessment
- Complete a comprehensive medical questionnaire reviewed by a Ro-affiliated physician
- Physician consultation determines appropriate medication and dosage
- Prescription filled through Ro's pharmacy network at standard delivery timelines
- Ongoing access to Ro's medical team and platform for monitoring and refills
Medications Offered
- ✓FDA-approved oral semaglutide pill (Wegovy pill), daily oral GLP-1 option
- ✓Compounded semaglutide injection, available alongside the oral option
- ✓No tirzepatide, oral GLP-1 options are semaglutide-based only
Pricing
Ro's entry cost is $39, the lowest barrier to starting GLP-1 treatment here. Ongoing medication costs vary by prescription type. Ro positions its oral option at roughly half the retail pharmacy list price for Wegovy; confirm the specific monthly cost directly at enrollment.
- ✓Lowest entry cost at $39, reduces financial risk for first-time users
- ✓FDA-approved oral semaglutide pill, the only daily pill option versus Willow's injections
- ✓Large, trusted telehealth brand with established credibility
- ✓Oral medication removes the injection barrier entirely
- ✓FDA approval provides regulatory assurance that compounded medications do not carry
- ✗No tirzepatide, patients who need a more potent GLP-1 have no escalation path within Ro
- ✗Standard pharmacy delivery is slower than Willow's 3-day guarantee
- ✗Ongoing medication costs after the initial $39 are variable and less transparent
- ✗Oral semaglutide has lower bioavailability than injectable, which may affect outcomes
Honest Tradeoffs
Pricing
Ro's $39 entry is a genuine low-barrier starting point, but it covers enrollment, not ongoing medication. Willow's $249/month is all-inclusive with no variable components. For a true long-term cost comparison, get a specific monthly medication quote from Ro after enrollment and compare it to Willow's fixed $249. Transparency strongly favors Willow.
Medication Types
This is where Willow and Ro diverge most. Ro's oral daily pill is FDA-approved, convenient, and needle-free. Willow's weekly injections have higher bioavailability, the STEP 1 injectable semaglutide trial showed 12-15% body weight reduction, while oral semaglutide achieves lower effective absorption at comparable doses. Tirzepatide, injection-only and exclusive to Willow here, showed up to 22.5% weight reduction in the SURMOUNT-1 trial. For patients where needles are not a barrier and maximizing clinical weight loss potential matters, Willow has a clear edge.
Doctor Involvement
Both use licensed physicians for intake and monitoring. Ro's larger platform supports a broader health ecosystem; Willow is specialized for GLP-1 delivery. Neither provides 24/7 medical access. For the specific use case of GLP-1 management, both are adequately supported. Patients with complex medical histories should supplement either program with in-person physician check-ins.
Delivery Speed
Willow's 3-day guarantee beats Ro's standard pharmacy timelines of 5-10 business days. For injectable users, that gap is felt most at the start of treatment. For oral medication users, the daily pill's convenience may offset the longer initial wait. Motivated patients starting injections will get medicated meaningfully faster with Willow.
Subscription Model
Willow is a straightforward flat monthly subscription. Ro separates enrollment from ongoing medication costs, which is more flexible for low-commitment testing but requires actively tracking the total monthly spend. Both allow cancellation without contracts. Willow's model is simpler; Ro's has a lower entry point but more variable ongoing costs.
Pricing Breakdown
| Aspect | Willow | Ro |
|---|---|---|
| Entry Cost | $249 first month (all-inclusive) | $39 to get started |
| Ongoing Monthly Cost | $249 flat rate | Varies by prescription type |
| Delivery Speed | 3 days guaranteed | Standard pharmacy (5-10 business days est.) |
| Pricing Transparency | Flat all-inclusive monthly | Variable based on prescription |
Medication Comparison
Semaglutide
Willow offers compounded injectable semaglutide (weekly subcutaneous injection). Ro offers FDA-approved oral semaglutide (daily pill). Both use semaglutide as the active GLP-1 receptor agonist, but injectable delivery achieves higher bioavailability, more drug reaches systemic circulation. The STEP 1 injectable trial showed 12.4% average body weight reduction over 68 weeks; oral semaglutide trials show efficacy but at lower effective absorption.
Tirzepatide
Willow offers compounded injectable tirzepatide, the most potent GLP-1 available, with up to 22.5% average body weight reduction in the SURMOUNT-1 trial. Ro does not offer tirzepatide in any form. No FDA-approved oral tirzepatide exists yet, so this is a market gap, not a Ro-specific limitation. For patients who want or may need tirzepatide, Willow is the only option here.
Which Provider Offers What
Willow: compounded injectable semaglutide and tirzepatide. Ro: FDA-approved oral semaglutide pill and compounded injectable semaglutide. Key gaps: tirzepatide (Willow only) and oral pill (Ro only). Medication preference and needle tolerance are the primary decision factors.
Results Expectations
Safety Considerations
Side Effects
Injectable and oral GLP-1s share a similar core side effect profile, nausea, vomiting, diarrhea, constipation, most pronounced during dose escalation. Oral semaglutide is taken on an empty stomach and some users report additional GI sensitivity from the dosing protocol itself. Both carry the same rare risks: pancreatitis, gallbladder disease, and thyroid C-cell concerns from animal studies (not confirmed in humans). New or severe abdominal pain should be reported to a provider immediately.
Doctor Supervision
Both require licensed physician oversight, a federal requirement. Willow focuses on streamlined GLP-1 delivery with monthly monitoring. Ro's broader platform provides physician access for GLP-1 management alongside other health services. Neither offers 24/7 medical professional access. Patients with complex medical histories, GI conditions, or thyroid or pancreatic issues should consult an in-person physician before starting either program.
Prescription Requirement
Both require BMI ≥30, or ≥27 with a qualifying comorbidity. Both screen for contraindications including medullary thyroid carcinoma, MEN2, and pancreatitis. One regulatory distinction: Ro's oral semaglutide is FDA-approved through the full New Drug Application process. Willow's compounded medications are prepared by FDA-regulated pharmacies but are not individually FDA-approved finished drug products. Both are legal; the distinction matters to some patients.
How We Evaluated These Providers
We evaluated both providers based on the following criteria:
- ✓Medication Format: The difference between injection-based and oral pill GLP-1 therapy, and what clinical evidence says about efficacy between delivery methods
- ✓Medication Range: Whether the provider offers semaglutide only or also tirzepatide, and the clinical significance for patients who may need a more potent option
- ✓Delivery Speed and Reliability: Whether a specific timeline is guaranteed versus estimated, and how meaningful the gap is for motivated new patients
- ✓Pricing Transparency: Whether the published cost is truly all-inclusive or whether variable pharmacy costs change the picture after enrollment
- ✓Regulatory Status: The distinction between FDA-approved medications (Ro) and compounded medications from FDA-regulated pharmacies (Willow)
- ✓Entry Barrier: The initial financial commitment required to start, and whether the low entry cost reflects true ongoing treatment cost
- ✓Patient Suitability: Which provider better serves needle-averse users, budget-conscious first-timers, patients who need tirzepatide, and high-motivation starters
Final Verdict
Editorial Take
Best for Budget Users
Ro's $39 entry is the lowest financial barrier to starting GLP-1 treatment here. For users testing whether GLP-1 therapy works before committing to higher monthly costs, it is the right starting point. Confirm the ongoing monthly medication cost after the $39 enrollment, it may be comparable to or exceed Willow's $249 depending on prescription type.
Best for Fast Results
Willow leads on two fronts: the 3-day delivery guarantee gets you medicated nearly a week sooner than Ro's standard pharmacy timelines, and tirzepatide access, showing up to 22.5% body weight reduction versus semaglutide's 12-15%, offers greater clinical potential. For patients prioritizing speed of treatment start and maximum weight loss outcome, Willow's injection model is the stronger choice.
Best for Doctor Supervision
Both provide adequate physician oversight for GLP-1 management. Ro's larger platform offers more infrastructure and brand stability. Willow's specialized GLP-1 focus means the clinical team is purpose-built for this specific treatment. Neither offers 24/7 access. Patients with significant comorbidities should supplement either program with regular in-person check-ins.
Best Premium Experience
Ro and Willow offer different premiums. Ro's is convenience and brand credibility, a daily pill from an FDA-approved medication, no injections. Willow's is clinical potency and fulfillment speed, access to the strongest GLP-1 medications including tirzepatide, delivered faster than any competitor. Choose based on whether you are optimizing for ease of use or maximum clinical efficacy.
Frequently Asked Questions
Read Our Full Reviews
Related Comparisons
Advertising & Affiliate Disclosure: We may receive compensation when you click on links to partners featured on this site. Our rankings and recommendations are based on our independent research methodology and editorial standards, not on sponsorship or payment. Some links are affiliate links, which means we may earn a commission at no extra cost to you if you make a purchase.
Medical Disclaimer: The content on this site is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider for medical questions, treatment decisions, or emergency care. Do not disregard professional medical advice or delay seeking it based on information found here.